TG Therapeutics' (TGTX) Q3 Results Solid; Roth Remains Positive into ASH Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to TG Therapeutics' (TGTX) Q3 Results Solid; Roth Remains Positive into ASH Conference
November 9, 2015 7:30 AM EST
NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2015 and recent company developments.
Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, stated, "During the third quarter, we achieved another major milestone for the Company in obtaining a Special Protocol Assessment for our UNITY-CLL trial, a study evaluating the safety and efficacy of our proprietary 1303 combination regimen in patients with front-line as well as previously treated CLL. This is a very important and exciting clinical trial... More
November 9, 2015 7:30 AM EST
NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2015 and recent company developments.
Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, stated, "During the third quarter, we achieved another major milestone for the Company in obtaining a Special Protocol Assessment for our UNITY-CLL trial, a study evaluating the safety and efficacy of our proprietary 1303 combination regimen in patients with front-line as well as previously treated CLL. This is a very important and exciting clinical trial... More
